Related Experiment Video
Updated: Jun 16, 2025
Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
Published on: April 13, 2015
Association of fibrotic markers with diastolic function after STEMI
Lawien Al Ali1, Wouter C Meijers2,3, Iris E Beldhuis2
1Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands. l.al.ali@umcg.nl.
Insights
Galectin-3 and soluble ST2 (sST2) did not predict diastolic dysfunction or long-term survival in STEMI patients. These fibrotic markers showed no association with cardiac outcomes in this non-diabetic cohort.
Area of Science:
- Cardiology
- Biomarkers
- Myocardial Infarction
Background:
- Cardiac fibrosis is linked to galectin-3 and soluble suppression of tumorigenicity-2 (sST2).
- Diastolic dysfunction and long-term outcomes are critical post-ST-elevated myocardial infarction (STEMI).
Purpose of the Study:
- To evaluate the prognostic value of galectin-3 and sST2 for diastolic dysfunction and survival in STEMI patients.
- To determine the association between fibrotic markers and cardiac outcomes following myocardial infarction.
Main Methods:
- Analysis of 236 non-diabetic STEMI patients from the GIPS-III cohort.
- Echocardiographic studies and plasma measurements at hospitalization and 4-month follow-up.
- Adjusted logistic mixed effects modeling and 5-year survival analysis.
Main Results:
- No association was found between galectin-3 or sST2 levels and the development of diastolic dysfunction over time.
- No significant differences in 5-year survival outcomes were observed between patients with normal versus abnormal galectin-3 or sST2 levels.
- Galectin-3 and sST2 were not predictive of diastolic dysfunction or survival in this STEMI cohort.
Conclusions:
- Galectin-3 and sST2 are not associated with the development of diastolic dysfunction in non-diabetic STEMI patients.
- These fibrotic markers do not appear to predict long-term survival outcomes in this specific patient population.
- Further research may be needed to clarify the role of these markers in different patient subgroups or cardiac conditions.
Abstract:
Galectin-3 and Suppression of tumorigenicity-2 (ST2) are known markers of cardiac fibrosis. We investigated the prognostic value of fibrotic markers for the development of diastolic dysfunction and long-term outcome in patients suffering an ST-elevated myocardial infarction (STEMI). We analyzed 236 patients from the GIPS-III cohort with available echocardiographic studies and plasma measurements at hospitalization and after 4 months follow-up. Adjusted logistic mixed effects modelling revealed no association between the occurrence of diastolic dysfunction over time with abnormal plasma levels of galectin-3 and ST2. We observed no differences regarding survival outcome at follow-up of 5 years between patients with normal versus abnormal values in both galectin-3 (P = 0.75), and ST2 (P = 0.85). In conclusion, galectin-3 and sST2 were not associated with the development of diastolic dysfunction in non-diabetic patients that presented with a STEMI.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...